Completed Infection & Immunity Cancer

Vaccinia virus entry, exit and evasion

In plain English

AI plain-English summary

Vaccinia virus, the live vaccine that eradicated smallpox, is still actively dismantling human cells to learn how it gets in, spreads, and hides from the immune system. This matters because viruses remain a potent threat—influenza and HIV are current examples—and understanding the fundamental mechanics of viral replication and immune evasion is essential for designing better vaccines and antiviral drugs. The project will track exactly how vaccinia virus enters a cell, how newly made virus particles are transported out, how they jump rapidly to neighbouring cells, and how the virus dodges the body’s immune response. If successful, this fundamental science will provide the detailed knowledge needed to engineer vaccinia virus into a safer, more immunogenic vaccine platform—not just for other infectious diseases, but also for cancer. There is no immediate practical application here; this is curiosity-driven research into the molecular machinery of a virus. But similar fundamental work on poxviruses in the past underpinned the smallpox eradication campaign and continues to shape vaccine design today.

View original technical description
Viruses remain a potent threat to human health as illustrated by the current epidemics caused by influenza virus and human immunodeficiency virus. Basic research on how viruses replicate, spread and evade our immunological defences is important in advancing our understanding of how viruses cause disease and will underpin the development of new vaccines and anti-viral drugs. This proposal concerns vaccinia virus (VACV), a poxvirus and the live vaccine that was used to eradicate smallpox. Although smallpox has been eradicated, VACV continues to be studied because i) it is possible to engineer VACV as a vaccine against other infectious diseases, and ii) the interaction between VACV and the host cell and immune system is providing novel, fundamental information about how viruses cause disease. This application will focus on how VACV enters cells, how new virus particles are transported out of the cell, how these virus particles spread rapidly to other cells, and how VACV evades the immune response to infection. The information obtained will facilitate the engineering of VACV as a safer and more immunogenic vaccine for infectious diseases and cancer.

View the original record at the funder ↗

Researchers

Geoffrey Smith (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

Poxvirus immune evasion strategies.
Understanding how viral innate immune evasion strategies affect adaptive immunity, and the application to vaccine development
Deciphering nanoscale interactions at the virus-host interface
Viral manipulation of DBC1: a novel strategy to promote cell survival and suppress inflammation
Restriction of DNA viruses by TRIM5a and ZAP / TRIM25 / KHNYN: mechanisms of restriction and viral evasion

Original classification

Research Grant

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.